Fingerprint
Dive into the research topics of 'Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II consortium study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically